ストックスクリーナーアプリを入手
49.58
2.38%
1.24
前日終値:
$48.34
開ける：
$47.85
24時間の取引高:
1.41M
Relative Volume:
0.65
時価総額：
$8.25B
収益：
$1.56B
当期純損益:
$152.72M
株価収益率:
55.13
EPS:
0.8994
ネットキャッシュフロー:
$221.80M
1週間 パフォーマンス:
-6.57%
1か月 パフォーマンス:
-5.54%
6か月 パフォーマンス:
+46.03%
1年 パフォーマンス:
+77.19%
1日の値動き範囲:
$47.71
$49.87
1週間の範囲:
$47.66
$53.88
52週間の値動き範囲:
$25.16
$55.67
Alkermes Plc Stock (ALKS) Company Profile
Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
49.49 | 8.79B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
17.17 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.08 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.06 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.00 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
525.55 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-06-29 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2025-11-11 | 開始されました | Truist | Buy |
| 2025-09-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
ALKS: Strong Q2 revenue, robust orexin pipeline progress, and LUMRYZ integration drive growth - TradingView
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down - Zacks Investment Research
Piper Sandler raises Alkermes stock price target on pipeline value - Investing.com
Alkermes Q2 Earnings Call Highlights - Yahoo Finance
Alkermes Q2 2026 slides: revenue surges 27% but acquisition costs squeeze - Investing.com
Earnings call transcript: Alkermes tops Q2 2026 estimates but shares fall premarket - Investing.com
ALKS Looks 64.8% Overvalued on GF Value™ - GuruFocus
Alkermes plc. Q2 2026: Revenue $496M, EPS $0— 10-Q Summary - TradingView
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Avadel deal pushes Alkermes (NASDAQ: ALKS) to H1 2026 net loss - Stock Titan
Why is Alkermes stock sliding today? - Investing.com
Piper Sandler raises Alkermes stock price target on pipeline value By Investing.com - Investing.com Canada
Is Alkermes PLC (ALKS) Overvalued After Q2 Earnings Beat Expecta - GuruFocus
Alkermes affirms FY26 sales guidance of $1.730B-$1.840B - scanx.trade
ALKS Looks 64.8% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Alkermes (ALKS) Reports Break-Even Earnings for Q2 - Yahoo Finance
Alkermes beats Q2 estimates, reaffirms revenue guidance - Investing.com
Earnings Flash (ALKS) Alkermes Public Company Posts Q2 EPS Breakeven, vs. FactSet Est of $0.03 Loss - marketscreener.com
Alkermes reports Q2 2026 revenue $496.0M, GAAP net income $0.5M, Adjusted EBITDA $139.2M - TradingView
Alkermes Q2 Revenue Rises to $496 Million as CEO Transition Nears - Quiver Quantitative
Alkermes plc Reports Second Quarter 2026 Financial Results - Yahoo Finance
Alkermes Plc (ALKS) Cash Flow - TradingKey
Alkermes Plc (ALKS) Institutional Confidence - TradingKey
Alkermes Plc (ALKS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alkermes Plc (ALKS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alkermes Plc (ALKS) Balance Sheet - TradingKey
Alkermes set to report earnings amid orexin frenzy and M&A buzz By Investing.com - Investing.com Australia
Alkermes set to report earnings amid orexin frenzy and M&A buzz - Investing.com UK
Alkermes Plc (ALKS) Income Statement - TradingKey
Alkermes Market Sentiment - Benzinga España
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alkermes Plc (ALKS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alkermes Plc (ALKS) Stock Analysis: Robust Revenue Growth Amidst Strategic Expansion - DirectorsTalk Interviews
Alkermes plc (8AK) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI
Alkermes plc (ALKS) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy - Sleep Review
Alkermes plc (ALKS) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alkermes plc (ALKS) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
0.38%
0.75%
大文字化:
|
ボリューム (24 時間):